Intelligence / Healthtech / New Clinical Trials / Eli Lilly and Company
Eli Lilly and Company
18 Nov 2026: Trial registered · A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 18 Nov 2026
- Title
- A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
- Conditions
- Healthy Participants
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07945314
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Eli Lilly and Company
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Eli Lilly and Company in our registers.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.